The Hidden Driver of Chronic Disease: Why I Keep Coming Back to Systemic Chronic Inflammation

By Tom O’Bryan, DC, CCN, DACBN, CIFM

Over the past few years, one question has been in the front of my mind: even though so many patients are doing “all the right things” at a very high level – investing in peptides, stem cells, laser therapies, GLP-1, red light devices, NAD IVs, wearables, and biohacking stacks – and even though some symptoms do reduce or disappear, they still don’t experience what any of us would call ‘vibrant vitality’. They feel better, but not truly well. The labs may look more polished, but oxidative stress markers are still way above normal, the technology more sophisticated, yet the day-to-day lived experience is still one of low-grade fatigue, fogginess, diminished clarity of thinking and a sense that the system never really gets to stand down.

That repeated pattern has me pushed to shift the core question. Instead of asking, “Which cutting-edge intervention should we add next?”, I’ve found it more useful to ask, “What is the background biology all of these interventions are being layered on top of?” This is where the concept of chronic inflammation becomes central. If a patient’s physiology is organized around an ongoing, low-grade inflammatory state – a body that is quietly, persistently behaving as though there is a life-threatening presence – then no matter how advanced the therapy, it is still trying to perform on top of a system locked in protective vigilance.

Immune activation is an inherited non-negotiable response to a perceived threat that saved our ancestors’ lives. We all have inherited these survival skills (and responses). In that light, the failure to reach vibrant vitality is not primarily a failure of peptides, or protocols; it is a reflection of unaddressed systemic chronic inflammation acting as the operating system underneath everything we do.

This is where David Furman’s work¹ becomes more than an interesting paper and starts to function as a paradigm. His Nature Medicine perspective on Chronic Inflammation in the Etiology of Disease Across the Life Span makes it very hard to treat systemic chronic inflammatory diseases now represent the most significant cause of death worldwide, and they identify long-term, low-grade systemic chronic inflammation (SCI) as a common fuel source for the progression of cardiovascular disease, cancer, diabetes, chronic kidney disease, NAFLD, autoimmune and neurodegenerative disorders.

For me, that was a "WHAT?" moment.

One mechanism, quietly running in the background while people more-or-less feel "fine," is driving most of what walks into our offices.

A Framework that Changed Everything

Once you frame SCI that way, the three-wheeled graph in Furman’s paper stops being ‘just a figure’ and becomes a practical teaching tool which every patient can understand.

 

On the left, you see the inputs that keep this inflammatory base state running – chronic infections, physical inactivity, visceral obesity, intestinal dysbiosis, diet, social isolation, psychological stress, disturbed sleep, circadian disruption, and xenobiotics.

In the middle, you see the non-negotiable immune system response designed as a life-saving mechanism.

And on the right, you see the downstream disease expressions we all recognize: metabolic syndrome and type 2 diabetes, NAFLD, cardiovascular disease, cancer, depression, autoimmune disease, neurodegeneration, sarcopenia, osteoporosis, immunosenescence.

I tell patients that those three interlocking wheels are a picture of how their biology works: when one wheel turns, it automatically drives the next, and eventually the third. And I give them a copy of the article, or at least the graph, to put on their refrigerator, as a daily reminder of what is thwarting their best efforts and why it is of critical importance to expand their paradigm of what it takes to get healthy.

As an example, when you eat something you should not have, you automatically activate SCI, which fuels your specific vulnerabilities, your ‘weak link in the chain’ (cognitive, CVD, Metabolic Syndrome …). Even if you feel “fine” when you eat the food, if your immune system perceives a threat, the response is non-negotiable = inflammation.

It helps them understand that SCI is not a vague idea but a real, mechanical process – an immune response to a perceived threat, and that their base state, their underlying ‘state of being’ is a state fueling and accelerating what the Italians coined ‘Inflammaging” (accelerated aging fueled by chronic inflammation).

Once patients can see SCI as their metabolic base state, the next step is to ask: what is actually turning that base state on? Alessio Fasano’s work on zonulin and gut permeability gives us a useful starting point. In his review ‘All Disease Begins in the (Leaky) Gut’², he describes zonulin as the only known physiological modulator of intestinal permeability and identifies ‘small exposure to large amounts of bacteria (bacterial overgrowth) and gluten’ as the “two most powerful triggers” of zonulin release and thus, increases gut permeability.

In other words, excessive exposure to Gram-negative bacteria (and their LPS-rich outer membranes) plus gluten, drive zonulin activation. There are not minor details; they are primary signals that open the epithelial door, increase macromolecule (antigen) and endotoxin trafficking, and initiate the innate immune response that feeds SCI.

Taken together with Furman’s paradigm, this gives us two foundational contributors to chronic immune activation:

1. Dysbiosis and barrier disruption driven by bacterial overgrowth and gluten-induced zonulin release
2. The resulting increase in endotoxin movement from the lumen into the system.

But in clinical practice, I think we need to name a third, closely related driver of SCI explicitly: LPS stored in tissues.

Once endotoxin has crossed a compromised barrier, it doesn’t just float harmlessly in the bloodstream; it embeds in tissue microenvironments – brain, vascular epithelium, adipose, liver, myocardium, …, where it engages TLR4 and other pattern-recognition receptors on resident immune, endothelial, and stromal cells. That tissue-level LPS signaling is what keeps local inflammation, fibrosis, and microglial activation going long after the original exposure, and it is a major reason SCI becomes a persistent operating system rather than a transient response.

So, if we put this together, we have three primary activators of systemic chronic inflammation that we can no longer afford to treat as peripheral issues:

• Excessive exposure to Gran-negative bacteria and their LPS-rich outer membranes (mainly from a dysbiotic microbiome)
• Gluten-driven zonulin release and the resulting loss of barrier integrity
• LPS deposition and retention in tissues, where it continues to tell the immune system it cannot stand down

In future articles, we’ll unpack what this means clinically. We’ll look more closely at how to recognize and measure these triggers – zonulin and permeability markers, endotoxin and bacterial antibody patterns, signs of tissue-level LPS effects in neurocognitive and cardiometabolic presentations – and how CellCore and Biocidin tools can be used to address each layer: restoring barrier function, reducing dysbiosis and biofilm-associated microbial load, and systematically lowering the tissue endotoxin burden that keeps SCI running in the background. My hope is that by bringing these mechanisms to the center of our reasoning, we can help more patients from “doing all the right things” to actually experiencing vibrant vitality.

Citations:

1. Chronic inflammation in the etiology of disease across the life span. Furman D, Campisi J,
2. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. Fasano A.F1000Res. 2020 Jan 31;9:F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1. eCollection 2020.